Supriya Lifescience profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026

Returns
	20.8%
Margins
	33.2%
	30.7%
	22.7%
Additional
	26.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health

₹ CrorePeersSTAR SPARC THYROCARE SHILPAMED VIYASH RUBICON YATHARTH PARKHOSPS

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	Last 12M 30/06/2026
Returns
Return on Invested Capital	—	—	—	—	20.80
Margins
EBITDA Margin	—	—	—	—	33.21
Pretax Margin	—	—	—	—	30.73
Net Income Margin	—	—	—	—	22.74
Additional
Effective Tax Rate	—	—	—	—	26.02

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.